Akèy › Kansè kolorektal › Texas › Dallas
Etid klinik pou Kansè kolorektal nan Dallas, TX
33 etid pou Kansè kolorektal ap chèche patisipan nan sit nan ak bò kote Dallas (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Ap rekriteFaz 1/2
- UT Southwest Simmons Cancer Center, Dallas
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Ap rekriteFaz 1
- Exelixis Clinical Site #89, Dallas
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Ap rekriteFaz 1
- SCRI at Mary Crowley, Dallas
- University of Texas Southwestern Medical Center, Dallas
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
Ap rekriteFaz 3
- Parkland Health and Hospital System, Dallas
- Texas Oncology DFW, Dallas
- UT Southwestern Medical Center, Dallas
A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- GSK Investigational Site, Dallas
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
Ap rekriteFaz 1
- Research Site, Dallas
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Ap rekriteFaz 3
- Texas Oncology DFW, Dallas
- UT Southwestern, Dallas
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Ap rekriteFaz 1/2
- Baylor, Scott and White Research Institute, Dallas
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
Ap rekriteFaz 3
- Parkland Memorial Hospital, Dallas
- UT Southwestern Simmons Cancer Center - RedBird, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Ap rekriteFaz 1
- Texas Oncology - DFW (Sammons CC), Dallas
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Ap rekriteFaz 1
- Texas Oncology - DFW (Sammons CC), Dallas
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
Ap rekriteFaz 1
- NEXT - Dallas, Dallas
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
Ap rekriteFaz 3
- University of Texas Southwestern Medical Center, Dallas
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
Ap rekriteFaz 3
- Clinical Study Site, Dallas
- Clinical Study Site, Dallas
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Ap rekriteFaz 1/2
- Texas Oncology, P.A., Dallas
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1/2
- Mary Crowley Cancer Research, Dallas
- Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Ap rekriteFaz 1/2
- Texas Oncology, Dallas
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
Ap rekriteFaz 3
- Texas Oncology - DFW, Dallas
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Ap rekriteFaz 2
- Texas Oncology - DFW, Dallas
A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer
Ap rekriteFaz 4
- University of Texas Southwestern Medical Center, Dallas
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
Ap rekriteFaz 1/2
- University of Texas Southwestern Medical Center, Dallas
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- NEXT Texas LLC - Dallas, Dallas
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Ap rekriteFaz 1
- UT Southwestern Simmons Cancer Center, Dallas
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Ap rekriteFaz 1
- Sarah Cannon Research Institute at Mary Crowley, Dallas
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
Ap rekriteFaz 1
- Sarah Cannon Research Institute at Mary Crowley, Dallas
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Ap rekriteFaz 1/2
- Mary Crowley Cancer Research, Dallas
Early-Onset Colorectal Cancer Patients Too Young for Screening
Ap rekriteEtid obsèvasyon
- Methodist Dallas Medical Center- Clinical Research Institute, Dallas
An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.
Ap rekriteFaz 2
- NGM Clinical Study Site, Dallas
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1/2
- NEXT Oncology - Dallas, Dallas
Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.
Ap rekriteFaz 1/2
- NEXT Oncology Dallas, Dallas
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
Ap rekriteFaz 4
- UT Southwestern Medical Center, Dallas
A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- NEXT Dallas, Dallas
A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors
Ap rekriteFaz 1
- NEXT Oncology, Dallas, Dallas
Etid Kansè kolorektal nan lòt vil
- Houston, TX102 etid
- New York City, NY78 etid
- Nashville, TN69 etid
- Boston, MA63 etid
- Los Angeles, CA59 etid
- Arlington, VA52 etid
- St. Louis, MO50 etid
- San Antonio, TX46 etid
- Philadelphia, PA44 etid
- Grand Rapids, MI40 etid
- Baldwin Park, CA37 etid
- Chicago, IL34 etid
Lòt etid nan Dallas
- Kansè nan tete55 etid
- Kansè Poumon ki pa ti selil52 etid
- Kansè Metastatik42 etid
- Ensifizyans kadyak42 etid
- Kansè (tout kalite)37 etid
- Kansè pwostat36 etid
- Obèsite30 etid
- Kansè ovè28 etid
- Kansè poumon27 etid
- Kansè vejik27 etid
- Kansè Endomèt24 etid
- Kansè renn (Kasinom selil renn)23 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.